泰格医药（300347）公告，全资附属公司株式会社泰格医药日本与日本MICRON原股东签署《股份转让 协议》，购买其持有的部分MICRON股权，本次转让完成后，日本泰格将持有MICRON56.37%股权。 MICRON成立于2005年，总部位于日本东京，员工人数超过160人，是一家专注于医学影像及临床试验 服务的CRO公司。MICRON截至2025年5月31日总资产7.81亿日元，净资产-4.52亿日元；2025年1-5月主 营业务收入9.4亿日元，净利润-6704.74万日元。 ...

（股 份 代 號：3347） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的 任 何 損 失 承 擔 任 何 責 任。 HANGZHOU TIGERMED CONSULTING CO., LTD. 自願性公告 關於全資子公司購買日本MICRON部分股權 杭州泰格醫藥科技股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） MICRON截 至2025年5月31日總資產78,094.76萬 日 元，淨 資 產-45,175.17萬 日 元；2025年1–5月主營業務收入93,959.78萬 日 元，淨 利 潤-6,704.74萬 日 元。 （以 上 數 據 未 經 審 計）。 一、股份購買概述 – 2 – 本 公 告 由 杭 州 泰 格 醫 藥 科 技 股 份 有 限 公 司（「本公司」）自 願 刊 發，藉 以 知 會 本 公 司 股 東 及 潛 在 投 資 者 有 關 本 公 司 的 最 ...

智通财经7月28日电，泰格医药(300347.SZ)公告称，公司持股5%以上股东、董事及总经理曹晓春计划自 公告披露之日起15个交易日之后的3个月内，以集中竞价和/或大宗交易方式减持公司股份不超过300万 股，占剔除回购专户股份数后公司总股本的0.3508%，占公司A股总股本的0.4098%。减持原因为偿还债 务及利息，降低质押融资风险。 泰格医药：持股5%以上股东曹晓春拟减持不超过300万股 ...

关于持股 5%以上股东减持股份的预披露公告 证券代码：300347 证券简称：泰格医药 公告编码（2025）032 号 杭州泰格医药科技股份有限公司 公司持股 5%以上股东曹晓春女士保证向公司提供的信息内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 杭州泰格医药科技股份有限公司（以下简称"公司"或"泰格医药"）于近日收到公司持 股5%以上股东、董事及总经理曹晓春女士关于计划减持公司股份的告知函：曹晓春女士 持有本公司股份51,661,774股（占剔除回购专户股份数后公司总股本的6.0413%，占公司 A股总股本的7.0575%），计划自本公告披露之日起15个交易日之后的3个月内（窗口期不 减持）以集中竞价和/或大宗交易方式减持公司股份不超过3,000,000股（占剔除回购专户 股份数后公司总股本的0.3508%，占公司A股总股本的0.4098%）。 现将相关事项公告如下： 一、股东的基本情况 | | | | 占剔除回购专户股 | 占剔除回购专户股 | | --- | --- | --- | --- | --- | | ...

金融界2025年7月28日消息，中欧医疗健康混合A(003095) 最新净值1.9608元，增长3.06%。该基金近1个 月收益率17.46%，同类排名439|4764；近6个月收益率29.85%，同类排名462|4579；今年来收益率 25.00%，同类排名902|4542。 中欧医疗健康混合A股票持仓前十占比合计54.73%，分别为：药明康德（10.39%）、恒瑞医药 （9.69%）、康龙化成（5.05%）、科伦药业（4.97%）、泰格医药（4.78%）、凯莱英（4.67%）、百利 天恒（4.11%）、信立泰（4.02%）、百济神州-U（3.66%）、新诺威（3.39%）。 简历显示：葛兰女士:中国籍。美国西北大学生物医学工程专业博士。历任国金证券股份有限公司研究 所研究员,民生加银基金管理有限公司研究员。2014年10月加入中欧基金管理有限公司,曾任研究员、中 欧明睿新起点灵活配置混合型证券投资基金基金经理(2015年1月29日起至2016年4月22日)、中欧瑾泉灵 活配置混合型证券投资基金基金经理(2015年3月16日起至2016年4月22日)、中欧瑾源灵活配置混合型证 券投资基金基金经理(2015年 ...

21世纪经济报道记者 唐唯珂 广州报道 医药板块的暖意正从创新药向产业链上下游扩散。 7月28日，药明康德(603259.SH)发布半年报，公司上半年实现营业收入207.99亿元，同比增长20.64%； 归属于上市公司股东的净利润85.61亿元，同比增长101.92%。 药明康德预计2025年持续经营业务收入重回双位数增长，增速从10-15%上调至13-17%。此外，药明康 德预计全年整体收入从人民币415-430亿元上调至人民币425-435亿元，将持续聚焦CRDMO核心业务， 持续提高生产经营效率。 这也让业内对CXO的市场信心倍增，而从市场数据也不难看出，CXO板块正迎来估值恢复。截至2025 年07月28日，港股通医药ETF（159776）上涨2.01%，最新价报1.321元，盘中成交额已达1.18亿元，换 手率94.78%。此前，7月25日医药股延续活跃，CXO概念股震荡走高，博腾股份涨超8%，康龙化成、 昭衍新药、泰格医药等跟涨。 创新药的"卖铲人"CXO（医药研发及生产外包）板块近期成为资金追逐焦点，相关ETF流通份额单月增 长近10亿份。 国家医保局推动高水平科技创新成果尽快进入临床，意味着临 ...

Investment Rating - The report maintains a positive outlook on innovative drugs and the industry chain, recommending continuous attention to this sector [1][5][24]. Core Viewpoints - The report highlights the sustained high prosperity of innovative drugs, with a focus on companies likely to see a revaluation, such as Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, and Huadong Medicine. It also emphasizes Biopharma/Biotech companies with innovative pipelines entering a growth phase, including PATEO, Innovent Biologics, BeiGene, and others [1][5][24]. - The A-share pharmaceutical sector outperformed the market in the third week of July 2025, with a 4.0% increase compared to a 0.7% rise in the Shanghai Composite Index. The report notes that the premium of the pharmaceutical sector relative to all A-shares is currently at a normal level of 86.8% [7][25][16]. - The Hong Kong pharmaceutical sector showed outstanding performance, with the Hang Seng Healthcare index rising by 12.0% and the Hong Kong Biotechnology index increasing by 13.6% during the same period [21][25]. Summary by Sections 1. Continuous Focus on Innovative Drugs and Industry Chain - The report emphasizes the ongoing high demand for innovative drugs and recommends companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others for potential investment [1][5][24]. 2. Performance of A-Shares Pharmaceutical Sector - In the third week of July 2025, the A-share pharmaceutical sector led with a 4.0% increase, outperforming the overall market. Notable sub-sectors included chemical raw materials and chemical preparations, with gains of 7.0% and 6.8% respectively [7][11][25]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector performed exceptionally well, with significant gains in the Hang Seng Healthcare and Biotechnology indices. In contrast, the U.S. pharmaceutical sector underperformed, with a decline of 2.5% in the S&P 500 Healthcare Select Sector [21][25].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry, expecting the industry index to outperform the market index by over 10% in the next six months [1][40]. Core Insights - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, rising by 7.84% from July 11 to July 24, 2025, exceeding the CSI 300's performance by approximately 4.13 percentage points [4][14]. - Most sub-sectors within the industry recorded positive returns during the same period, with the medical research outsourcing and raw materials sectors leading with increases of 14.23% and 9.30%, respectively [4][15]. - Approximately 91% of stocks in the industry achieved positive returns, with notable performers including Borui Pharmaceutical, which saw a weekly increase of 78.98% [16]. Summary by Sections 1. Market Review - The SW pharmaceutical and biotechnology industry outperformed the CSI 300 index, with a rise of 7.84% from July 11 to July 24, 2025, surpassing the CSI 300 by about 4.13 percentage points [14]. - Most sub-sectors recorded positive returns, particularly medical research outsourcing and raw materials, which increased by 14.23% and 9.30%, respectively [15]. - About 91% of stocks in the industry had positive returns, with Borui Pharmaceutical leading at 78.98% [16]. 2. Industry News - The report highlights the ongoing progress of the 11th batch of national drug procurement, with significant updates provided during a government open day event on July 22, 2025 [4][28]. - The announcement of the 11th batch of national drug procurement included a notification for drug information submission, which was highly anticipated [4][28]. 3. Company Announcements - Yekang Pharmaceutical announced that its subsidiary received FDA approval for clinical trials of YKYY029 injection for hypertension treatment [29]. 4. Industry Outlook - The report maintains an "Overweight" rating for the industry, citing a continuous rise in the pharmaceutical and biotechnology sector driven by positive sentiment towards innovative drugs and improved financing data [30]. - The report suggests focusing on investment opportunities within the innovative drug supply chain and highlights several companies across various segments, including medical devices, pharmaceutical commerce, and innovative drugs [30][32].

Summary of Key Points from Conference Call Records Industry Overview - **Pharmaceuticals**: The focus is on innovative drugs and price optimization in the procurement process. Over 100 drug varieties are applying for inclusion in the innovative drug directory as of July 24, 2025 [1]. The 11th batch of centralized procurement has started, emphasizing the principle that new drugs will not be included in centralized procurement [1]. - **Vaccines**: Companies like Zhifei Biological and Nanjing Xinbai are expanding their vaccine pipelines, with a total of 15 products expected to be launched by the end of 2024 [2]. - **Liquid Cooling Technology**: The adoption of liquid cooling in high-end AI chips is increasing, with predictions that over 50% of new data center projects will use liquid cooling technology by 2025 [6]. The global data center cooling market is expected to grow from $18.78 billion in 2025 to $42.48 billion by 2032 [6]. - **Coal and Steel Industries**: The coal industry is experiencing price increases due to high demand driven by power consumption [12]. The steel industry is facing intense price competition, with a focus on improving product quality and phasing out outdated capacity [13]. Core Company Insights - **KQ-2003 CAR-T Therapy**: Key partnership between Kayi Pharmaceutical and ERIGEN LLC for the exclusive overseas licensing of KQ-2003, with potential milestone payments reaching $1.33 billion [2]. - **Nanjing Xinbai**: Introduced the first FDA-approved CAR-T therapy for solid tumors, currently in Phase III clinical trials [2]. - **Hainan Rubber**: The company is the largest natural rubber producer in China, with a significant market share and plans for joint ventures in the duty-free sector [27]. - **Jinlong Co.**: Engaging in the acquisition of Shenzhen Benmao Technology to enhance its capabilities in intelligent computing centers [23]. Additional Important Information - **Regulatory Changes**: The National Development and Reform Commission is seeking public opinion on a draft amendment to the Price Law, aiming to regulate unfair pricing behaviors and combat "involution" in competition [11]. - **Market Dynamics**: The coal and steel industries are under pressure to stabilize prices and improve quality, with government interventions to curb excessive competition [12][13]. - **Technological Advancements**: The development of static pressure equipment is crucial for solid-state battery production, with significant market potential exceeding 10 billion yuan [19]. Conclusion The conference call records highlight significant developments across various industries, particularly in pharmaceuticals, vaccines, liquid cooling technology, and traditional sectors like coal and steel. Companies are adapting to regulatory changes and market demands while exploring innovative partnerships and technological advancements to maintain competitive advantages.

Core Viewpoint - The pharmaceutical sector in A-shares and Hong Kong stocks is experiencing strong performance driven by favorable policy stimuli, with significant inflows into biotechnology ETFs [1][4]. Group 1: Market Performance - The Hang Seng Biotechnology ETF (513280) saw an intraday increase of over 2%, currently up 0.83%, while the Biopharmaceutical ETF (159839) experienced a net subscription of 5 million units [1][3]. - A-share biopharmaceuticals are performing strongly, with notable gains in CXO stocks such as Kanglong Chemical (up over 7%) and Zhaoyan New Drug (up over 4%) [3][4]. Group 2: Policy Environment - Since 2025, there have been multiple high-level proposals to optimize drug procurement and support innovative drugs, indicating a positive policy environment for the pharmaceutical industry [4][5]. - The 11th batch of national drug procurement is beginning, with expectations for optimized rules and price reductions, moving away from a focus on minimum pricing to quality control [4][5]. Group 3: Investment Opportunities - The introduction of a dual-directory model for commercial health insurance and basic medical insurance is expected to create a buffer for high-value innovative drugs, enhancing their commercialization prospects [4][5]. - The optimization of procurement policies is anticipated to improve market sentiment and lead to a recovery in the pharmaceutical sector, with a focus on innovation and internationalization [5][6].